KBC Group
TVTX icon

KBC Group’s Travere Therapeutics TVTX Stock Holding History

KBC Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$84K Sell
2,843
-1,344
-32% -$40.2K ﹤0.01% 1426
2025
Q4 		$160K Hold
4,187
– – ﹤0.01% 1004
2025
Q3 		$100K Hold
4,187
– – ﹤0.01% 1263
2025
Q2 		$62K Hold
4,187
– – ﹤0.01% 1488
2025
Q1 		$75K Buy
+4,187
New +$85K ﹤0.01% 1639

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KBC Group's TVTX Position: Q1 2026 in Review

KBC Group reduced its Travere Therapeutics (TVTX) stake by 32% in Q1 2026, selling an estimated $40.2K and leaving 2,843 shares worth $84K. The position accounts for ﹤0.01% of the portfolio, ranked #1426.

KBC Group first reported a position in TVTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $160K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • KBC Group held 2,843 shares of Travere Therapeutics worth $84K as of Q1 2026.
  • KBC Group sold 1,344 Travere Therapeutics shares in Q1 2026, an estimated $40.2K.
  • Travere Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1426 holding.
  • KBC Group first reported a position in Travere Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • KBC Group's Travere Therapeutics position peaked at $160K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.